Drug Approval | November 06, 2025
Bayer's finerenone approved in India for heart failure
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
With over two decades of extensive experience, Lal has established himself as a transformational leader in the FMCG and consumer goods sectors
Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Arora brings over 30 years of experience in the pharmaceutical and healthcare industry
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Subscribe To Our Newsletter & Stay Updated
